Butyrylcholinesterase (BCHE)

Overview

Butyrylcholinesterase (BChE; also known as pseudocholinesterase, plasma cholinesterase, or non-specific cholinesterase) is a serine hydrolase enzyme encoded by the BCHE gene in humans. It belongs to the cholinesterase family and preferentially hydrolyzes butyrylcholine, though it can also act on acetylcholine and a broad range of choline esters. Unlike its close paralog Acetylcholinesterase (AChE) (AChE), which is concentrated at neuromuscular junctions and synapses, BChE is expressed widely across tissues including the liver, plasma, intestine, and brain. Structurally, BChE possesses a catalytic triad (Ser-His-Glu) within a deep, gorge-shaped active site, flanked by a peripheral anionic site and a choline-binding pocket—features that are exploited extensively in drug design efforts.

BChE plays a complex and context-dependent role in cholinergic neurotransmission. Under normal physiological conditions, it contributes modestly to the hydrolysis of acetylcholine; however, in advanced Alzheimer's disease (AD), AChE activity declines markedly while BChE activity progressively compensates, making BChE an increasingly important therapeutic target as neurodegeneration advances. Beyond neurological disease, BChE is implicated in lipid metabolism, glucose homeostasis linked to insulin resistance, and detoxification of xenobiotics. Its expression has also been identified in certain tumor microenvironments, extending its relevance beyond neuropharmacology into oncology. These diverse roles have made BChE the subject of intense multidisciplinary research, spanning synthetic medicinal chemistry, natural product pharmacology, parasitology, and cancer biology.

Recent Publications Summary

Recent studies have continued to evaluate Butyrylcholinesterase (BCHE/BChE) as a therapeutic target in Alzheimer’s disease, most often in the context of dual cholinesterase inhibition or selective BChE inhibition. Several reports combined synthesis of new small molecules with in silico docking, molecular dynamics, and enzyme assays to identify compounds with strong binding to BChE and favorable inhibitory profiles 42481895Jul42179001May42050895Apr41965189Apr41871474Mar41797133Mar41691754Feb41628818Feb. In these studies, coumarin carboxamides, flavonoid-fused aminoquinolines, chiral anthranilic diamides, benzothiazole-linked oxadiazoles, benzimidazole derivatives, and thieno[3,2-d]pyrimidine hybrids were all explored as cholinesterase inhibitors, with BChE activity frequently exceeding or complementing AChE inhibition 42481895Jul42179001May42050895Apr41871474Mar41797133Mar41691754Feb41628818Feb.

Among the most active compounds, several showed low micromolar to nanomolar BChE inhibition. In a coumarin-carboxamide series, all derivatives outperformed tacrine against BChE, and docking/MM-GBSA analyses identified a BChE-bound complex with strong predicted affinity 42481895Jul. A flavonoid-fused aminoquinoline, (±)-7-amino-6-phenyl-6H-chromeno[4,3-b]quinoline (3aa), inhibited human BChE with an IC50 of 0.096 μM and was more potent against BChE than AChE 42179001May. Chiral anthranilic diamide derivatives also showed significant inhibition of both enzymes, with compounds 7a and 7b reported to have nanomolar-level activity and to outperform tacrine 42050895Apr. Similarly, benzothiazole-linked oxadiazoles identified K11 and K7 as notable BChE inhibitors with IC50 values comparable to the reference drug, while docking supported their binding to BChE 41797133Mar. The benzimidazole analog IMS48 inhibited BChE with an IC50 of 1.85 μM and also showed in vivo benefit in an Alzheimer’s disease model 41628818Feb.

Other work focused on selective BChE inhibition and multifunctional profiles relevant to neurodegeneration. A pyranone-carbamate hybrid, E14, was designed as a selective BChE inhibitor with negligible AChE activity, showing competitive inhibition against equine and human BChE and also suppressing lipopolysaccharide-induced nitric oxide production in BV2 microglial cells 42008868Apr. Thieno[3,2-d]pyrimidine-phenolic Mannich base hybrids produced low-nanomolar inhibition of both AChE and BChE, with compounds 5 and 9 among the most active and supported by docking, molecular dynamics, and MM-GBSA analyses 41871474Mar. Coumarin-benzothiazole hybrids were likewise developed as dual AChE/BuChE inhibitors using a chromatographic screening platform designed to improve analytical specificity over conventional Ellman-based assays 41965189Apr. In addition, natural-product-rich extracts from fruit tree leaves and Epimedium pubigerum were reported to inhibit BChE alongside other enzyme targets, suggesting broader bioactivity of plant-derived mixtures 41861736Mar41806791Mar. Overall, these publications reinforce BChE as an important target in Alzheimer’s disease drug discovery and highlight ongoing efforts to develop potent, selective, and multifunctional inhibitors 42481895Jul42335451Jun42179001May42050895Apr42008868Apr41965189Apr41871474Mar41797133Mar41691754Feb41628818Feb.

What Changes, What Holds

1. BChE remains a drug-discovery target, but the new work mainly extends the inhibitor pipeline rather than changing its biological role
REINFORCES Multiple recent medicinal chemistry programs continue to treat BChE as a relevant target in Alzheimer’s disease, especially for dual cholinesterase inhibition or selective BChE blockade 42481895Jul42179001May. That strengthens the baseline view of BChE as a major therapeutic focus in neurodegeneration, but it does not alter the underlying account of the enzyme’s physiology or disease association. The main change is momentum: the target is being pursued with increasingly diverse chemotypes and computational support.

2. Potent BChE inhibition is now being achieved across several new chemotypes, sharpening the case for selective targeting
REINFORCES Recent compounds show that BChE can be inhibited at low micromolar to nanomolar potency, including agents that outperform tacrine or favor BChE over AChE 42481895Jul42179001May. This does not revise the baseline, which already places BChE at the center of Alzheimer’s drug design, but it does make that rationale more concrete by showing that strong, selective inhibition is chemically tractable. The unresolved issue is translation: potency alone does not establish clinical advantage.

3. Selective and multifunctional BChE inhibitors are expanding the therapeutic concept without displacing the established role in neurodegeneration
REINFORCES The new selective inhibitor and dual-target programs reinforce BChE’s place in Alzheimer’s disease while adding anti-inflammatory or assay-method refinements that may matter for lead optimization 42008868Apr41965189Apr. These findings leave the baseline intact: BChE remains a neuropharmacologic target, and the broader roles in metabolism and detoxification are unchanged. What is new is the design direction toward compounds that combine enzyme inhibition with ancillary biological effects, though their practical value remains unsettled.

Overview update candidates: strong BChE-selective inhibition as a drug-discovery theme; continued expansion of potent dual or multifunctional cholinesterase inhibitor scaffolds.